Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ActiveOxy is a specific brand of 1% hydrogen peroxide solution that has been investigated as a topical antiseptic intervention for COVID-19. In a clinical trial led by Aga Khan University, the solution was utilized as both a gargling agent and a nasal lavage to reduce the intraoral and nasopharyngeal viral load in patients with mild to moderate disease. The mechanism of action involves the oxidative properties of hydrogen peroxide, which acts as a broad-spectrum antiseptic capable of debriding surfaces and potentially inactivating viral particles through the generation of free radicals that damage viral proteins and nucleic acids. This approach was studied as a cost-effective prophylactic and therapeutic adjunct to reduce viral shedding and protect healthcare workers in resource-limited settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ActiveOxy.